Open AccessFKBP52 and FKBP51 differentially regulate the stability of estrogen receptor in breast cancer
Author(s) -
Makoto Habara,
Yuki Sato,
Takahiro Goshima,
Masashi Sakurai,
Hideki Imai,
Hideyuki Shimizu,
Yuta Katayama,
Shunsuke Hanaki,
Takahiro Masaki,
Masahiro Morimoto,
Sayaka Nishikawa,
Tatsuya Toyama,
Midori Shimada
Publication year - 2022
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.2110256119
Subject(s) - breast cancer , estrogen receptor , cancer research , oncology , interactome , transcriptome , estrogen , endocrine system , biology , medicine , cancer , bioinformatics , gene expression , genetics , hormone , gene
Significance Estrogen receptor α (ERα) is a transcription factor that induces cell proliferation and exhibits increased expression in a large subset of breast cancers. We comprehensively searched for indicators of poor prognosis in ERα-positive breast cancer through the multiple databases, including interactome, transcriptome, and survival analysis, and identified FKBP52. We found that two immunophilins, FKBP52 and FKBP51, have opposing effects on ERα stability and propose that therapeutic targeting of FKBP52 could be useful for the prevention and treatment of ERα-positive breast cancers, including endocrine therapy–resistant breast cancers.